Error loading player: No playable sources found

2460

Donald O. Castell, MD, Lecture: GERD Diagnosis from Lyon to Chicago to Padova: Do All Roads Eventually Lead to Rome?

Date
May 18, 2024

Society: AGA

LIVE STREAM SESSION

The diagnosis of GERD is being updated using the Lyon Consensus 2.0 (updated in 2023), which takes into account a modern diagnosis of GERD, symptoms of GERD, optimal testing as well as metrics and thresholds used to diagnose conclusive GERD. The Padova classification (completed in 2023) addresses evaluation of the GERD patient needing antireflux surgery and other invasive approaches. GERD overlaps with motility disorders as well as disorders of gut-brain interaction, characterized using Chicago Classification (2021)and Rome criteria (2023-24). This symposium brings leaders from each of these consensus processes to discuss how to use each set of criteria, and where each process intersects with the others.

Presentations:

THE MODERN DIAGNOSIS OF GERD USING LYON CONSENSUS 2.0
HOW DOES CHICAGO CLASSIFICATION V4.0 HELP GERD DIAGNOSIS?
THE PADOVA CONSENSUS: HRM BEFORE AND AFTER ANTIREFLUX SURGERY
RELEVANCE OF ROME CRITERIA TO GERD DIAGNOSIS
PANEL DISCUSSION

Moderators

Speaker Image for Joan Chen
University of Michigan
Speaker Image for C. Prakash Gyawali
Washington University School of Medicine

Speakers

Speaker Image for Rena Yadlapati
University of California San Diego
Speaker Image for Renato Salvador
University of Padova
Speaker Image for John Pandolfino
Northwestern University

Related Products

Thumbnail for Josephine and Michael Camilleri, MD, Lecture: State of the Art
Josephine and Michael Camilleri, MD, Lecture: State of the Art
DDW attendees learn the state of the art for diagnostic evaluation and clinical care for Esophageal, Gastroduodenal and Lower GI Neurogastroenterology and Motility…
Thumbnail for Irritable Bowel Syndrome Clinical
Irritable Bowel Syndrome Clinical
TREATMENT WITH THE HISTAMINE 1 RECEPTOR ANTAGONIST EBASTINE FOR NON-CONSTIPATED IRRITABLE BOWEL SYNDROME: A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL